Alyssa S. Meester
Research Subjects
Alyssa S. Meester has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Erica Caffarini
OhioHealth Riverside Methodist Hospital
2 shared publications John Dillis
OhioHealth Research Institute
2 shared publicationsMarie M. Lockhart
OhioHealth Research Institute
2 shared publicationsMichael Young
Ohio Health Riverside Methodist Hospital
2 shared publications- Adam Smith
Advanced Heart and Vascular Center, OhioHealth Riverside Methodist Hospital, Columbus, OH, USA
1 shared publication Angela Harding
OhioHealth Riverside Methodist Hospital, Columbus, OH, USA
1 shared publication
Latest Publications
- 16 January 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (5) , 424-431
Impact of Initial Heparin Rates on Reaching Goal Anti-Xa and Activated Partial Thromboplastin Time Within 48 Hours of Initiation in Patients With Mechanical Circulatory Support
Background: Patients receiving mechanical circulatory support (MCS) devices should receive anticoagulation to avoid clotting of the circuit and to lower risk of acute thrombosis. Patients at our institution are initiated on UFH at 12 units/kg/h; however, patients weighing > 83 kg are weight-capped (WC) at an initial rate of 1000 units/h, which equates to < 12 units/kg/h. Objective: The objective of this study was to compare time to goal anticoagulation in patients receiving MCS who were WC compared to those who were not. Methods: A retrospective cohort study was completed of patients who received UFH during admission for an MCS device and monitored by activated partial thromboplastin time (aPTT) or anti-Xa levels. The primary outcome was the percentage of patients between groups who achieved goal anti-Xa or aPTT within 48 h of UFH initiation. Results: A total of 56 patients were included, with 27 not weight-capped (NWC) and 29 WC. There was no significant difference between groups in percentage of patients who achieved goal anti-Xa or aPTT within 48 h (88.9% NWC vs 89.7% WC, P = 0.93). There was no significant difference in time to goal between groups. The NWC group had more bleeding events (4 vs 0, P = 0.031), with no difference in thrombosis. Conclusion: There was no difference in the percentage of patients reaching goal aPTT or anti-Xa within 48 h when UFH was WC. However, future studies should compare differences in time to goal anticoagulation between different UFH intensity protocols.
- 16 January 2026
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (5) , 424-431
Impact of Initial Heparin Rates on Reaching Goal Anti-Xa and Activated Partial Thromboplastin Time Within 48 Hours of Initiation in Patients With Mechanical Circulatory Support
Background: Patients receiving mechanical circulatory support (MCS) devices should receive anticoagulation to avoid clotting of the circuit and to lower risk of acute thrombosis. Patients at our institution are initiated on UFH at 12 units/kg/h; however, patients weighing > 83 kg are weight-capped (WC) at an initial rate of 1000 units/h, which equates to < 12 units/kg/h. Objective: The objective of this study was to compare time to goal anticoagulation in patients receiving MCS who were WC compared to those who were not. Methods: A retrospective cohort study was completed of patients who received UFH during admission for an MCS device and monitored by activated partial thromboplastin time (aPTT) or anti-Xa levels. The primary outcome was the percentage of patients between groups who achieved goal anti-Xa or aPTT within 48 h of UFH initiation. Results: A total of 56 patients were included, with 27 not weight-capped (NWC) and 29 WC. There was no significant difference between groups in percentage of patients who achieved goal anti-Xa or aPTT within 48 h (88.9% NWC vs 89.7% WC, P = 0.93). There was no significant difference in time to goal between groups. The NWC group had more bleeding events (4 vs 0, P = 0.031), with no difference in thrombosis. Conclusion: There was no difference in the percentage of patients reaching goal aPTT or anti-Xa within 48 h when UFH was WC. However, future studies should compare differences in time to goal anticoagulation between different UFH intensity protocols.
- 4 September 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (3) , 211-218
Beyond the Bedside: Utilization of an On-Call Pharmacist to Bridge Gaps in Clinical Coverage for Select Critically ill Populations
Purpose: To describe the utilization of an on-call critical care pharmacist to bridge gaps in clinical coverage for subspecialized critically ill populations. Methods: In October 2022, a 24/7 on-call team of medical and cardiac ICU pharmacists was established to field questions regarding patients with mechanical circulatory support and pulmonary hypertension. On-call pharmacists were available via centralized telephone number Monday through Friday from 4:00 p.m. to 8:00 a.m., and at all hours on weekends. Information characterizing calls received was collected in an electronic database. A review of all database entries through March 2025 was conducted and descriptive statistics were used to quantify calls received, time spent, multidisciplinary team member engagement, and types of interventions. Results: On-call pharmacists received 207 calls and documented 218 interventions. Calls were most often received between the hours of 4:00 p.m. and 8:00 a.m., and the median time spent per call was 10 minutes (IQR 5-20 minutes). On-call critical care pharmacists received the most calls for ECMO patients (38.2%), followed by pulmonary hypertension (26.1%) and Impella® patients (20.8%). The majority of inquiries were from pharmacists (35.7%), followed by advanced practice providers (33.3%) and physicians (21.3%). Anticoagulation and hemostasis was the most commonly cited intervention category (56.4%). Conclusion: In the absence of an onsite critical care pharmacist, a 24/7 on-call critical care pharmacist was utilized by members of the multidisciplinary team to bridge gaps in clinical coverage. Further research is needed to determine the pharmacoeconomic and clinical impacts of on-call critical care pharmacists when onsite resources are unavailable.
- 4 September 2025
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 39 (3) , 211-218
Beyond the Bedside: Utilization of an On-Call Pharmacist to Bridge Gaps in Clinical Coverage for Select Critically ill Populations
Purpose: To describe the utilization of an on-call critical care pharmacist to bridge gaps in clinical coverage for subspecialized critically ill populations. Methods: In October 2022, a 24/7 on-call team of medical and cardiac ICU pharmacists was established to field questions regarding patients with mechanical circulatory support and pulmonary hypertension. On-call pharmacists were available via centralized telephone number Monday through Friday from 4:00 p.m. to 8:00 a.m., and at all hours on weekends. Information characterizing calls received was collected in an electronic database. A review of all database entries through March 2025 was conducted and descriptive statistics were used to quantify calls received, time spent, multidisciplinary team member engagement, and types of interventions. Results: On-call pharmacists received 207 calls and documented 218 interventions. Calls were most often received between the hours of 4:00 p.m. and 8:00 a.m., and the median time spent per call was 10 minutes (IQR 5-20 minutes). On-call critical care pharmacists received the most calls for ECMO patients (38.2%), followed by pulmonary hypertension (26.1%) and Impella® patients (20.8%). The majority of inquiries were from pharmacists (35.7%), followed by advanced practice providers (33.3%) and physicians (21.3%). Anticoagulation and hemostasis was the most commonly cited intervention category (56.4%). Conclusion: In the absence of an onsite critical care pharmacist, a 24/7 on-call critical care pharmacist was utilized by members of the multidisciplinary team to bridge gaps in clinical coverage. Further research is needed to determine the pharmacoeconomic and clinical impacts of on-call critical care pharmacists when onsite resources are unavailable.
- 18 January 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (3) , 221-225
Enoxaparin Venous Thromboembolism Prophylaxis Dosing in Critically Ill Underweight Patients
Purpose: Optimal dosing of VTE prophylaxis for specific patient populations remains an area of concern as insufficient evidence exists regarding dosing for underweight patients. The purpose of this study is to compare the incidence of major bleeding events in underweight patients given different prophylactic doses of enoxaparin. Methods: This is a retrospective analysis performed at multiple hospitals within a single health care system. Patients with a BMI < 18.5 kg/m 2 were divided into 2 groups depending on whether they received at least 1 prophylactic dose of enoxaparin 30 mg subcutaneously once daily or enoxaparin 40 mg subcutaneously once daily. Underweight adult patients were included if they were admitted to an ICU for at least 48 hours and received at least 1 dose of enoxaparin for VTE prophylaxis during their ICU admission. The primary aim was to compare the incidence of clinically significant bleeding between dosing strategies. Secondary aims included the incidence of VTE during admission, ICU length of stay, overall hospital length of stay, and all-cause mortality 30 days post-discharge. Results: A total of 310 patients met inclusion criteria for this study, with 80 patients in the 30 mg group and 230 patients in the 40 mg group. There was no significant difference in major bleeding events between the 2 groups ( P = .61). No significant differences in incidence of VTE ( P = .455 ), ICU length of stay ( P = .466), overall hospital stay ( P = .502), or all-cause mortality ( P = .925) were found between groups. Conclusions: No difference was found in clinically significant bleeding between underweight critically ill patients receiving VTE prophylaxis with enoxaparin 30 mg once daily or 40 mg once daily. Further studies are needed to evaluate the optimal dosing of VTE prophylaxis with enoxaparin in underweight patients.
- 18 January 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 60 (3) , 221-225
Enoxaparin Venous Thromboembolism Prophylaxis Dosing in Critically Ill Underweight Patients
Purpose: Optimal dosing of VTE prophylaxis for specific patient populations remains an area of concern as insufficient evidence exists regarding dosing for underweight patients. The purpose of this study is to compare the incidence of major bleeding events in underweight patients given different prophylactic doses of enoxaparin. Methods: This is a retrospective analysis performed at multiple hospitals within a single health care system. Patients with a BMI < 18.5 kg/m 2 were divided into 2 groups depending on whether they received at least 1 prophylactic dose of enoxaparin 30 mg subcutaneously once daily or enoxaparin 40 mg subcutaneously once daily. Underweight adult patients were included if they were admitted to an ICU for at least 48 hours and received at least 1 dose of enoxaparin for VTE prophylaxis during their ICU admission. The primary aim was to compare the incidence of clinically significant bleeding between dosing strategies. Secondary aims included the incidence of VTE during admission, ICU length of stay, overall hospital length of stay, and all-cause mortality 30 days post-discharge. Results: A total of 310 patients met inclusion criteria for this study, with 80 patients in the 30 mg group and 230 patients in the 40 mg group. There was no significant difference in major bleeding events between the 2 groups ( P = .61). No significant differences in incidence of VTE ( P = .455 ), ICU length of stay ( P = .466), overall hospital stay ( P = .502), or all-cause mortality ( P = .925) were found between groups. Conclusions: No difference was found in clinically significant bleeding between underweight critically ill patients receiving VTE prophylaxis with enoxaparin 30 mg once daily or 40 mg once daily. Further studies are needed to evaluate the optimal dosing of VTE prophylaxis with enoxaparin in underweight patients.
- 16 June 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (3) , 273-285
Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to April 2023, using the search terms “MYK-461,” “mavacamten,” “CK-3773274,” and “aficamten.” Studies were limited to English-based literature, human subjects, and clinical trials resulting in the inclusion of 13 articles. ClinicalTrials.gov was also used with the same search terms for ongoing and completed trials. Study Selection and Data Extraction: Only phase II and III studies were included in this review except for pharmacokinetic studies that were used to describe drug properties. Data Synthesis: CMIs enable cardiac muscle relaxation by decreasing the number of myosin heads that can bind to actin and form cross-bridges. Mavacamten, the first Food and Drug Administration (FDA)-approved drug in this class, has been shown to improve hemodynamic, functional, and quality of life measures in HCM with obstruction. In addition, aficamten is likely to become the next FDA-approved CMI with promising phase II data and an ongoing phase III trial expected to release results in the next year. Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs: CMIs provide a novel option for obstructive hypertrophic cardiomyopathy, particularly in those not suitable for septal reduction therapy. Utilization of these agents requires knowledge of drug interactions, dose titration schemes, and monitoring parameters for safety and efficacy. Conclusions: CMIs represent a new class of disease-specific drugs for treatment of HCM. Cost-effectiveness studies are needed to delineate the role of these agents in patient therapy.
- 16 June 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (3) , 273-285
Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM). Data Sources: A literature search was conducted on PubMed from origin to April 2023, using the search terms “MYK-461,” “mavacamten,” “CK-3773274,” and “aficamten.” Studies were limited to English-based literature, human subjects, and clinical trials resulting in the inclusion of 13 articles. ClinicalTrials.gov was also used with the same search terms for ongoing and completed trials. Study Selection and Data Extraction: Only phase II and III studies were included in this review except for pharmacokinetic studies that were used to describe drug properties. Data Synthesis: CMIs enable cardiac muscle relaxation by decreasing the number of myosin heads that can bind to actin and form cross-bridges. Mavacamten, the first Food and Drug Administration (FDA)-approved drug in this class, has been shown to improve hemodynamic, functional, and quality of life measures in HCM with obstruction. In addition, aficamten is likely to become the next FDA-approved CMI with promising phase II data and an ongoing phase III trial expected to release results in the next year. Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs: CMIs provide a novel option for obstructive hypertrophic cardiomyopathy, particularly in those not suitable for septal reduction therapy. Utilization of these agents requires knowledge of drug interactions, dose titration schemes, and monitoring parameters for safety and efficacy. Conclusions: CMIs represent a new class of disease-specific drugs for treatment of HCM. Cost-effectiveness studies are needed to delineate the role of these agents in patient therapy.